Building a healthier tomorrow
At Intercept, our focus is to develop and deliver novel medicines for those living with rare and serious liver diseases.
Nishele, Living with Serious Liver Disease
Innovating to solve some of today’s toughest medical challenges
Using key discoveries in the field of liver health, we’re advancing treatments for rare and serious liver diseases. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
Working to improve the lives of people with serious liver diseases
Intercept Pharmaceuticals is committed to transforming the future for people with serious liver diseases. We are trailblazers, driven by a passion to stand by patients who deserve more hope and better solutions.
Research focused on liver diseases with high unmet need
Our research is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
Biology in pursuit of better health
Farnesoid X Receptor (FXR) biology is at the core of our therapeutic research. This treatment modality has applications for severe liver conditions such as severe alcohol-associated hepatitis.
About Us
Since 2002, we’ve pioneered a novel scientific platform to answer critical needs in the liver health community and deliver on our mission to build a healthier tomorrow for people with rare and serious liver diseases.
Working at Intercept
Intercept Pharmaceuticals, a wholly owned subsidiary of Alfasigma, is part of a rapidly expanding global biopharmaceutical leader with a presence in over 100 countries. Our mission is rooted in advancing innovative therapies for people living with serious liver diseases, and our team is dedicated to bringing hope to those whose health journeys demand new solutions.
If you thrive on curiosity, value diverse perspectives, embrace bold thinking, and are
passionate about creating life-changing solutions, you belong here—where innovation
drives everything we do.
